UK Markets closed

Orchard Therapeutics plc (ORTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.5949+0.0179 (+3.10%)
As of 02:02PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.5770
Bid0.5900 x 1400
Ask0.6000 x 3100
Day's range0.5790 - 0.6200
52-week range0.4100 - 3.1800
Avg. volume903,870
Market cap74.659M
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)-1.2120
Earnings date28 Feb 2022 - 04 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.67
  • Globe Newswire

    Orchard Therapeutics Reports Second Quarter 2022 Financial Results and Reviews Recent Business Highlights

    Additional Libmeldy® reimbursement discussions advancing across Europe with product sales totaling $3.1M in Q2 and $8.2M YTD OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven abstracts accepted at SSIEM highlight potential of HSC gene therapy platform to address difficult-to-treat neurodegenerative disorders Ended Q2 with $170.9M of cash and investments and runway into 2024; R&D expenses in Q2 declined 22% from the prior quarter BOSTON and LONDON, Aug. 04, 2022 (GLOBE NEW

  • Globe Newswire

    Orchard Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Commercial Progress

    Product sales for Libmeldy totaled $5.1M for the first two commercial patients treated in Q1 2022 Libmeldy® access and reimbursement expanding with agreements now signed in three major European markets recognizing its clinical value OTL-200 U.S. BLA filing for MLD on track for late 2022 / early 2023 Seven upcoming presentations at ASGCT highlight application of HSC approach including clinical and research programs Cash and investments of approximately $200M provide runway into 2024 BOSTON and LO

  • Globe Newswire

    Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond

    BOSTON and LONDON, May 10, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today outlined seven presentations from across its platform to be featured at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19 in Washington, D.C. Featured presentations include updated results on the OTL-203 clinical program for mucopolysaccharidosis type I Hurler syndrome (MPS-IH), as well as several accepted abstracts highlighting